Literature DB >> 19458490

Minocycline as a potential therapeutic agent in neurodegenerative disorders characterised by protein misfolding.

Wendy Noble1, Claire J Garwood, Diane P Hanger.   

Abstract

Many neurodegenerative disorders share common features including the accumulation of aggregated misfolded proteins, neuroinflammation and the induction of apoptosis. While the contributions of each of these individual elements to neuronal death remain unclear, a commonly used antibiotic, minocycline, has been shown to reduce the progression and severity of disease in several models of neurodegeneration by variously downregulating these molecular pathways. Here we discuss the evidence for the potential of minocycline as a broad-specificity therapeutic agent for those neurodegenerative diseases that are characterized by the presence of misfolded proteins.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19458490      PMCID: PMC2712603          DOI: 10.4161/pri.3.2.8820

Source DB:  PubMed          Journal:  Prion        ISSN: 1933-6896            Impact factor:   3.931


  70 in total

Review 1.  Tau, tangles, and Alzheimer's disease.

Authors:  Lester I Binder; Angela L Guillozet-Bongaarts; Francisco Garcia-Sierra; Robert W Berry
Journal:  Biochim Biophys Acta       Date:  2005-01-03

2.  Caspase-1 is activated in neural cells and tissue with amyotrophic lateral sclerosis-associated mutations in copper-zinc superoxide dismutase.

Authors:  P Pasinelli; D R Borchelt; M K Houseweart; D W Cleveland; R H Brown
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-22       Impact factor: 11.205

3.  Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia.

Authors:  J Yrjänheikki; R Keinänen; M Pellikka; T Hökfelt; J Koistinaho
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-22       Impact factor: 11.205

4.  Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins.

Authors:  M P Lambert; A K Barlow; B A Chromy; C Edwards; R Freed; M Liosatos; T E Morgan; I Rozovsky; B Trommer; K L Viola; P Wals; C Zhang; C E Finch; G A Krafft; W L Klein
Journal:  Proc Natl Acad Sci U S A       Date:  1998-05-26       Impact factor: 11.205

5.  Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease.

Authors:  V O Ona; M Li; J P Vonsattel; L J Andrews; S Q Khan; W M Chung; A S Frey; A S Menon; X J Li; P E Stieg; J Yuan; J B Penney; A B Young; J H Cha; R M Friedlander
Journal:  Nature       Date:  1999-05-20       Impact factor: 49.962

6.  Effects of minocycline on Fas-mediated fulminant hepatitis in mice.

Authors:  Heng-Cheng Chu; Yi-Ling Lin; Huey-Kang Sytwu; Shin-Hua Lin; Ching-Len Liao; You-Chen Chao
Journal:  Br J Pharmacol       Date:  2005-01       Impact factor: 8.739

7.  Blockade of PKCdelta proteolytic activation by loss of function mutants rescues mesencephalic dopaminergic neurons from methylcyclopentadienyl manganese tricarbonyl (MMT)-induced apoptotic cell death.

Authors:  V Anantharam; M Kitazawa; C Latchoumycandane; A Kanthasamy; A G Kanthasamy
Journal:  Ann N Y Acad Sci       Date:  2004-12       Impact factor: 5.691

8.  Tau truncation during neurofibrillary tangle evolution in Alzheimer's disease.

Authors:  Angela L Guillozet-Bongaarts; Francisco Garcia-Sierra; Matthew R Reynolds; Peleg M Horowitz; Yifan Fu; Tianyi Wang; Michael E Cahill; Eileen H Bigio; Robert W Berry; Lester I Binder
Journal:  Neurobiol Aging       Date:  2004-12-16       Impact factor: 4.673

Review 9.  Clinical potential of minocycline for neurodegenerative disorders.

Authors:  David Blum; Abdelwahed Chtarto; Liliane Tenenbaum; Jacques Brotchi; Marc Levivier
Journal:  Neurobiol Dis       Date:  2004-12       Impact factor: 5.996

10.  Aggregation and motor neuron toxicity of an ALS-linked SOD1 mutant independent from wild-type SOD1.

Authors:  L I Bruijn; M K Houseweart; S Kato; K L Anderson; S D Anderson; E Ohama; A G Reaume; R W Scott; D W Cleveland
Journal:  Science       Date:  1998-09-18       Impact factor: 47.728

View more
  25 in total

1.  Minocycline ameliorates LPS-induced inflammation in human monocytes by novel mechanisms including LOX-1, Nur77 and LITAF inhibition.

Authors:  Tao Pang; Juan Wang; Julius Benicky; Juan M Saavedra
Journal:  Biochim Biophys Acta       Date:  2012-01-27

2.  Early Minocycline and Late FK506 Treatment Improves Survival and Alleviates Neuroinflammation, Neurodegeneration, and Behavioral Deficits in Prion-Infected Hamsters.

Authors:  Syed Zahid Ali Shah; Deming Zhao; Giulio Taglialatela; Sher Hayat Khan; Tariq Hussain; Haodi Dong; Mengyu Lai; Xiangmei Zhou; Lifeng Yang
Journal:  Neurotherapeutics       Date:  2017-04       Impact factor: 7.620

Review 3.  Murine models of Alzheimer's disease and their use in developing immunotherapies.

Authors:  Thomas Wisniewski; Einar M Sigurdsson
Journal:  Biochim Biophys Acta       Date:  2010-05-13

4.  Cypermethrin-induced nigrostriatal dopaminergic neurodegeneration alters the mitochondrial function: a proteomics study.

Authors:  Sonal Agrawal; Ashish Singh; Pratibha Tripathi; Manisha Mishra; Pradhyumna Kumar Singh; Mahendra Pratap Singh
Journal:  Mol Neurobiol       Date:  2014-04-24       Impact factor: 5.590

Review 5.  Immunotherapeutic approaches for Alzheimer's disease.

Authors:  Thomas Wisniewski; Fernando Goñi
Journal:  Neuron       Date:  2015-03-18       Impact factor: 17.173

Review 6.  Immunotherapy for Alzheimer's disease.

Authors:  Thomas Wisniewski; Fernando Goñi
Journal:  Biochem Pharmacol       Date:  2014-01-09       Impact factor: 5.858

7.  Evaluation of prion deposits and microglial activation in scrapie-infected mice using molecular imaging probes.

Authors:  Pu-Jiao Song; Céline Barc; Nicolas Arlicot; Denis Guilloteau; Serge Bernard; Pierre Sarradin; Sylvie Chalon; Lucette Garreau; Hank F Kung; Frédéric Lantier; Jackie Vergote
Journal:  Mol Imaging Biol       Date:  2010-12       Impact factor: 3.488

8.  Novel immunological approaches for the treatment of Alzheimer's disease.

Authors:  Priyanka Sabharwal; Thomas Wisniewski
Journal:  Zhongguo Xian Dai Shen Jing Ji Bing Za Zhi       Date:  2014

Review 9.  Immunotherapeutic approaches for Alzheimer's disease in transgenic mouse models.

Authors:  Thomas Wisniewski; Allal Boutajangout
Journal:  Brain Struct Funct       Date:  2009-12-10       Impact factor: 3.270

Review 10.  Developing therapeutic vaccines against Alzheimer's disease.

Authors:  Thomas Wisniewski; Eleanor Drummond
Journal:  Expert Rev Vaccines       Date:  2015-12-11       Impact factor: 5.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.